BioTuesdays

Author - Leonard Zehr

Adamis Pharma
Developments

Adamis resubmits NDA to FDA for epinephrine pen

Adamis Pharmaceuticals (NASDAQ:ADMP) has resubmitted its NDA to the FDA for its Epinephrine Pre-filled Syringe (PFS) product candidate for the emergency treatment of anaphylaxis. The resubmission is intended to address...

December 16, 2016
IntelGenx Logo
Developments

IntelGenx, RedHill license Rizaport in Korea

IntelGenx (OTCQX:IGXT; TSX-V:IGX) and RedHill Biopharma (NASDAQ,:RDHL; TASE:RDHL) have signed an exclusive license agreement with Pharmatronic for the commercialization of Rizaport in South Korea. Rizaport is a...

December 14, 2016
ContraVir Logo
Developments

ContraVir updates action of HBV inhibitor

ContraVir Pharmaceuticals (NASDAQ:CTRV) provided new insights into the mechanism of action of its hepatitis B (HBV) cyclophilin inhibitor, CRV431, showing that it effectively blocks a critical interaction between HBV X...

December 8, 2016
Developments

MaRS and KHIDI in commercialization deal

MaRS Innovation and the Korea Health Industry Development Institute (KHIDI) signed a five-year global partnership agreement to commercialize the latest advances in biomedical and healthcare innovations, which is...

December 1, 2016
oramed
Developments

Oramed GLP-1 analog found safe in study

Oramed Pharmaceuticals (NASDAQ:ORMP) has successfully concluded a Phase 1b study of ORMD-0901, its oral GLP-1 analog, in Type 2 diabetes patients. The study showed ORMD-0901 to be safe and well tolerated, having no...

November 29, 2016
Feature

In conversation with Jason Kolbert

By Len Zehr As head of healthcare research and as the senior biotechnology analyst with Maxim Group, Jason Kolbert has worked extensively in the healthcare sector. This includes pharma experience with Schering-Plough in...

November 22, 2016